{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:34:02Z","timestamp":1790364842713,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug-induced psoriasis has been increasingly recognized, but the spectrum of potential triggering medications remains incompletely characterized. We aimed to identify the drugs potentially associated with psoriasis using a large-scale and real-world pharmacovigilance analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Firstly, disproportionality analyses were used to detect psoriasis-related drug signals. Furthermore, Multivariable logistic regression and Bayesian shrinkage models were applied to evaluate the consistency of the detected associations after adjustment for available demographic and reporting-related factors. Finally, stratified analyses by sex, age, and reporter type were conducted to assess signal robustness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 30 drugs showed significant associations with psoriasis. These signals involved several pharmacological categories, including anti-infective agents (e.g., Abacavir, Fluconazole, Moxifloxacin, Sulfamethoxazole), anti-inflammatory and immunomodulatory drugs (e.g., Celecoxib, Tofacitinib), cardiovascular agents (e.g., Acebutolol, Telmisartan, Clonidine), neuropsychiatric drugs (e.g., Nortriptyline, Temazepam, Zopiclone, Wellbutrin), hormonal agents (e.g., Progesterone, Prometrium), and respiratory medications (e.g., Ventolin). Bayesian correction generally attenuated extreme effect estimates but confirmed the robustness of most signals. The stratified analysis also approve the above results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that multiple drug classes are associated with psoriasis signals in pharmacovigilance data. These results highlight the importance of early recognition of drug-associated psoriasis and may assist clinicians in medication review and risk stratification in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1888496","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:52:05Z","timestamp":1784713925000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug-associated psoriasis: a pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"17","author":[{"given":"Sha","family":"Yi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chengdu Integrated TCM & Western Medicine Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuda","family":"Huoshen","sequence":"additional","affiliation":[{"name":"School of Stomatology, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengmei","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunmi","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Stomatology, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/PTT.S126727","article-title":"Drug-induced psoriasis: clinical perspectives","volume":"7","author":"Balak","year":"2017","journal-title":"PsoriasisAuckl. NZ"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.semarthrit.2010.04.003","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis","volume":"40","author":"Collamer","year":"2010","journal-title":"Seminars Arthritis Rheumatism"},{"key":"B4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10753-025-02385-3","article-title":"Neuroimmune crosstalk in psoriasis: mechanisms and therapeutic implications","volume":"49","author":"Gao","year":"2025","journal-title":"Inflammation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12016-017-8617-4","article-title":"Skin manifestations of inflammatory bowel disease","volume":"53","author":"Greuter","year":"2017","journal-title":"Clin. Reviews Allergy and Immunology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/jcpe.70040","article-title":"Pharmacovigilance-based identification and mechanistic exploration of periodontitis-related drugs","volume":"53","author":"Huoshen","year":"2026","journal-title":"J. Clin. Periodontol."},{"key":"B7","first-page":"32","article-title":"Drug-provoked psoriasis: is it drug induced or drug aggravated? understanding pathophysiology and clinical relevance","volume":"3","author":"Kim","year":"2010","journal-title":"J. Clinical Aesthetic Dermatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S1473-3099(07)70161-5","article-title":"HIV-Associated psoriasis","volume":"7","author":"Mamkin","year":"2007","journal-title":"Lancet Infect. Diseases"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e81636","DOI":"10.7759\/cureus.81636","article-title":"Dupilumab-induced psoriasis in a patient with prurigo nodularis: a case report","volume":"17","author":"Ogawa","year":"2025","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2050313x241284003","DOI":"10.1177\/2050313X241284003","article-title":"A case of probable drug-induced psoriasis to dapagliflozin","volume":"12","author":"Qureshi","year":"2024","journal-title":"SAGE Open Medical Case Reports"},{"key":"B11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. Journal Medical Sciences"},{"key":"B12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Reviews Allergy and Immunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1541-0420.2008.01058.x","article-title":"Joint regression analysis of correlated data using gaussian copulas","volume":"65","author":"Song","year":"2009","journal-title":"Biometrics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/j.jaad.2014.09.032","article-title":"Psoriasis as a manifestation of HIV-Related immune reconstitution inflammatory syndrome","volume":"72","author":"Tripathi","year":"2015","journal-title":"J. Am. Acad. Dermatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","article-title":"Drug-induced psoriasis. Recognition and management","volume":"1","author":"Tsankov","year":"2000","journal-title":"Am. Journal Clinical Dermatology"},{"key":"B16","first-page":"910","article-title":"Localized amyloidosis of the digestive tract","volume":"49","author":"Yuda","year":"1991","journal-title":"Nihon Rinsho Jpn. Journal Clinical Medicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2174\/0118715303383036250807095142","article-title":"Revisiting the association between beta-blockers and psoriasis: evidence from real-world data","author":"Zheng","year":"2025","journal-title":"Endocr. Metabolic and Immune Disorders Drug Targets"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1888496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T12:35:37Z","timestamp":1785933337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1888496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":17,"alternative-id":["10.3389\/fphar.2026.1888496"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1888496","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1888496"}}